Patritumab deruxtecan monotherapy (HERTHENA-Lung01) — EGFR-mutant NSCLC post-osimertinib + platinum
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PATRITUMAB-DERUXTECAN |
|---|
| ID | REG-PATRITUMAB-DXD-NSCLC-POST-EGFR |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
HERTHENA-Lung01 (phase II, n=225): patritumab deruxtecan in EGFR-mutant NSCLC after EGFR-TKI (≥80% post-osimertinib) + platinum-based chemo. ORR 29.8%, mDOR 6.4 mo, mPFS 5.5 mo, intracranial ORR 33.3% in measurable brain mets. Activity independent of HER3 expression (no selection biomarker required). HERTHENA-Lung02 phase III vs platinum chemo (post-osimertinib) read out 2024 with PFS benefit but no OS benefit; FDA CRL 2024-06 cited manufacturing concerns, not efficacy. Distinct from Dato-DXd (TROP2 target) — sequencing question post- HERTHENA-Lung02 / TROPION-Lung05.
Used By
Indication
IND-NSCLC-EGFR-POST-OSI-PATRITUMAB-DXD- IND-NSCLC-EGFR-POST-OSI-PATRITUMAB-DXD